Do you want to read an article? Please log in or register.
Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial
COPD
Related content
RECOMMENDED
COPD
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis
Vogelmeier CF, Kerwin EM, Bjermer LH, Tombs L, Jones PW, Boucot IH, Naya IP, Lipson DA, Compton C, Barnes N, Maltais F
doi: 10.1177/1753466620968500
RECOMMENDED
Further Publications
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beaty E, Girard M, Stowasser S, Zoz D, Maher TM, SENSCIS trial investigators.
doi: 10.1016/S2213-2600(20)30330-1
RECOMMENDED
COPD
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res
Vogelmeier CF, Jones PW, Kerwin EM, Boucot IH, Maltais F, Tombs L, Compton C, Lipson DA, Bjermer LH
doi: 10.1186/s12931-021-01859-w
RECOMMENDED
COPD
Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Ther Adv Respir Dis.
Sethi S, Donohue JF, Ferguson GT, Barnes CN, Crater GD
doi: 10.1177/1753466620905278.Visit the original publication at ncbi.nlm.nih.gov
RECOMMENDED
COPD
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis
Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA
doi: 10.1177/1753466620963021
RECOMMENDED
COPD
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis
Cochrane Database Syst Rev.
Oba Y, Keeney E, Ghatehorde N, Dias S
doi: 10.1002/14651858.
Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis
COPD.
Zou Y, Xiao J, Yang DH, Li J, Chen Q
doi: 10.3109/
COMMENTED
COPD
Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials
Thorax.
Jolliffe DA, Greenberg L, Hooper RL, Mathyssen C, Rafiq R, de Jongh RT, Camargo CA, Griffiths CJ, Janssens W, Martineau AR
doi: 10.1136/thoraxjnl-2018-212092.
RECOMMENDED
COPD
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, Vahdati-Bolouri M, Vogelmeier CF
doi: 10.1186/s12931-019-1193-9.